Grail (GRAL) Stock News
$GRAL · NASDAQ · 4 stories in 30 daysBORSA has published 4 stories on Grail (GRAL) in the past 30 days, 1 of them high impact. BORSA’s news read on GRAL is bullish at 61/100, −1 over 24 hours, based on 5 company events over the past 30 days. Grail’s next earnings report is scheduled for Wednesday, Nov 11.
The wire on $GRAL
newest first · updated · direct subject stories onlyFDA advisors back Grail's cancer-finding blood test
FDA advisors back Grail's cancer-finding blood test.
bullish 65 · impact 70FDA Advisors Recommend Approval of Grail Multicancer Blood Test
An FDA advisory panel voted 7-2 that Grail's Galleri blood test's benefits outweigh risks, with unanimous support for safety. Approval could come in months, giving Grail a lead over rivals Guardant Health and Abbott. Grail shares rose 35% ahead of the vote. Medicare coverage may follow in 2029.
neutral 50 · impact 40